Combined Use of Erythropoietin and Granulocyte Colony-Stimulating Factor Does Not Decrease Blood Transfusion Requirements During Induction Therapy for High-Risk Neuroblastoma: A Randomized Controlled Trial

Abstract

The addition of EPO to the G-CSF regimen provides no benefit for patients receiving intensive induction chemotherapy for high-risk neuroblastoma.

Erythropoietin protects neuroblastoma cells against etoposide and vincristine by activating ERK and AKT pathways but has no effect in kidney cells

“…In addition, Epo has been documented to protect the kidney from the nephrotoxic effect of chemotherapeutic agents [25]. However, the use of Epo on neuroblastoma patients has not been extensively evaluated [37]. In addition, there is evidence showing that administration of Epo to tumour cells expressing EpoR induces cell proliferation [19] and tumour cell survival [2].…”

“…Children with high-risk neuroblastoma frequently develop anaemia as a result of nephrotoxic and myelotoxic chemotherapy, bone marrow metastasis, malnutrition, and haemorrhage. Most of them require red blood cell transfusions [37].…”

RECOMBINANT HUMAN ERYTHROPOIETIN BETA THERAPY: An Effective Strategy to Reduce Transfusion Requirement in Children Receiving Anticancer Treatment

“…Twenty-seven and 30% of the patients received RT in the study and control groups, respectively. All patients were followed for 15.16 ± 4.98 (9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25) weeks. The durations of follow-up for epoetin and control groups were similar (16.04 ± 4.78 [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] and 14.70 ± 4.53 [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] weeks, res...…”

“…The response rate in adults, as measured by elevation of hemoglobin and diminution of RBC transfusion requirements, ranges from 21 to 85% [6][7][8]. To date, some important studies have examined the role of rHuEPO in children with cancer by utilizing epoetin alfa [10][11][12][13][14][15][16][17][18][19]. In our prospective and historical controlled study, epoetin beta was used to find out the effect of rHuEPO on hemoglobin (Hb) concentrations and RBC transfusion requirement in children receiving CT ± radiotherapy (RT).…”

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model

“…This process revealed an additional five primary studies. [58][59][60][61][62] In restricting eligibility to ESA treatments evaluated in accordance with their European marketing authorisation with respect to starting dose, 47 studies were excluded (a list of these studies together with the study characteristics can be found in Appendix 6). In total, 23 primary studies 17,48,[50][51][52][53][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78] reported in 34 publications 17,48,[50][51][52][53][58][59][60] were judged to meet the inclusion criterion for the review (Table 10); study characteristics are summarised in Appendix 7.…”